Clinical Trials Logo

Clinical Trial Summary

To date, the radiation oncologist are missing biomarkers predictive of response/resistance to RT in order to identify patients who may benefit from RT and personalize the RT schedule. Our proposal is to conduct a cohort study aiming at identifying transcriptomic biomarkers predictive of sensitivity and/or resistance to RT in limbs STS patients


Clinical Trial Description

Whether RT should be performed pre or post-operatively is still a debated question. To date, the radiation oncologist are missing signature of response/resistance to RT in order to identify patients who may benefit from RT and personalize the RT schedule. Therefore, predicting the likelihood of response/resistance to RT is essential. The individual exploration with high-throughput approaches will participate in describing biological mechanisms involved in STS tumor cell pan-resistance, thus identifying potential molecular targets that could be inhibited to reverse intrinsic radioresistance. In this context, our proposal is to conduct a cohort study aiming at identifying transcriptomic signature predictive of sensitivity and/or resistance to RT in limbs STS patients. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05739084
Study type Observational
Source Centre Leon Berard
Contact Marie -Pierre SUNYACH, MD
Phone +33(0)4 78 78 28 28
Email MariePierre.SUNYACH@lyon.unicancer.fr
Status Recruiting
Phase
Start date November 23, 2022
Completion date November 23, 2025

See also
  Status Clinical Trial Phase
Completed NCT00385203 - The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST). Phase 2
Terminated NCT02536183 - A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors Phase 1
Recruiting NCT00687778 - 11C-Acetate PET/CT Non-FDG-Avid Tumors N/A
Recruiting NCT04506008 - Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas Phase 2
Terminated NCT02575066 - Clinical Study of Concurrent Pazopanib and Radiotherapy for Non-metastatic Sarcoma Patients Phase 2
Completed NCT04223583 - Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride Capsule Phase 4
Recruiting NCT04425967 - Short Course Of Preoperative Radiotherapy in Head and Neck-, Trunk- and Extremity Soft Tissue Sarcomas N/A
Not yet recruiting NCT03946943 - Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Phase 2
Withdrawn NCT00881595 - Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas Phase 2
Completed NCT00423254 - Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer. Phase 1
Completed NCT00276302 - Safety Study of IPI-504 in Patients With Gastrointestinal Stromal Tumors (GIST) or Soft Tissue Sarcomas (STS) Phase 1
Withdrawn NCT03149120 - Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas Phase 2
Completed NCT01830153 - RAD001 in Advanced Sarcoma Phase 2
Completed NCT02636725 - Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas Phase 2